Filed under: Investing
Shire ( ) is one of the globe's biggest drug companies. It's a major player in ADHD and rare disease, and the company has been rumored as a takeover target by Allergan, and recently AbbVie announced its third attempt to buy the company.
Shire's focus to date has remained squarely on growth, rather than dividends; however, the company has a solid track record of double-digit dividend payout increases over the past decade.
Given that Shire has already lost patent protection for its ADHD drug Adderall and will lose patent protection on another important ADHD drug later this year, investors are right to wonder if that dividend streak can continue.
In the following slideshow you'll learn whether I think Shire's dividend is safe and see how Shire's dividend matches up to suitor AbbVie and industry peer Novartis .
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
The article Is Shire's Dividend Safe? originally appeared on Fool.com.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Read | Permalink | Email this | Linking Blogs | Comments